Q1 showed Tilray can grow across beverage, distribution and international channels, but the report also showed how acquisition-related costs and other non-cash charges are overwhelming that operating progress. The key question is whether gross profit growth can start flowing through to cash and operating income.
Key figures
Million USD | Q1 2027 | Q1 2026 | Change |
|---|---|---|---|
Revenue | 257.15 | 209.50 | +22.7 % |
Gross profit | 77.51 | 57.47 | +34.9 % |
Operating income | -24.05 | 2.09 | -1249.8 % |
Net income | -43.14 | -0.32 | -42.82 |
Operating cash flow | -16.54 | -1.34 | -15.20 |
Gross margin | 30.1 % | 27.4 % | +2.7 pp |
Operating margin | -9.4 % | 1.0 % | -10.4 pp |
Net margin | -16.8 % | -0.2 % | -16.6 pp |
Figures in USD, as reported. Margins are computed from the reported lines.
Growth came from the newer platform, not from cannabis
Revenue rose 22.7% to $257.1 million in Q1, but the mix matters more than the headline: beverage revenue increased 82% to $101.5 million, distribution rose 14% to $84.3 million, while cannabis revenue fell to $56.1 million from $64.5 million and wellness was flat at $15.3 million 8-K. Beverage growth reflected the acquisition of BrewDog, while management also highlighted 71% EMEA revenue growth led by medical cannabis, beverage and pharmaceutical distribution 8-K.
That mix shift helps explain why gross profit grew faster than revenue. Gross profit increased 34.9% to $77.5 million and gross margin expanded to 30.1% from 27.4%, with beverage gross margin improving to 41% from 38% and cannabis gross margin rising to 39% from 36% even as cannabis sales declined 8-K.
Better gross margins did not survive the operating expense step-up
The quarter turned from operating income of $2.09 million to an operating loss of $24.05 million as operating expenses rose 83% to $101.6 million, far outpacing gross profit growth 25. The biggest increases were in general and administrative expense, marketing and promotion, amortization, restructuring costs and transaction costs, with transaction costs alone rising to $4.8 million from $0.4 million 19.
This weakens the quality of the quarter relative to the gross profit story. Management said net loss was driven predominantly by non-cash charges, and the filing shows a swing in non-operating results to a $7.8 million expense from $3.8 million of income a year earlier, while income tax also moved to expense 25. Even so, some of the pressure was plainly cash or recurring enough to matter, including higher G&A, marketing, restructuring and transaction spending 8-K25.
Cannabis margin improved, but the Canadian business is not yet stable
The cannabis segment did not drive growth, and the filing gives concrete reasons. In Canada, market share fell to 7.4% from 7.9% in the immediately preceding quarter, primarily because a planned cultivation strain rotation temporarily affected whole flower supply and an out-of-stock at a componentry vendor hurt straight-edge pre-rolls 6.
Management’s response was to favor profitability over volume by prioritizing higher-margin premium brands and redirecting approximately 1.0 metric tonnes to international markets that are expected to generate higher-margin sales 8-K. That supports the improved cannabis gross margin, but it also suggests domestic revenue pressure is being managed through mix and channel choices rather than underlying category strength, especially with ongoing price compression in Canada 67.
The balance sheet message is mixed despite debt reduction
Tilray ended the quarter with cash, restricted cash and marketable securities of $221.4 million and said it reduced total outstanding debt by $42 million fiscal year to date 8-K. It also reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million and said results are typically more weighted toward the second half, especially the fourth quarter 8-K.
But liquidity is not a closed issue. Operating cash flow was negative $16.54 million in Q1, and after quarter-end the company amended its credit facility so financial covenants would not be tested for the quarter ended August 31, 2026, while borrowing availability under the revolving credit facility remains limited until covenant testing resumes 8-K. That does not negate the cash balance, but it means balance-sheet flexibility depends on execution improving from here 67.
What to watch next
Whether second-half weighting is enough to support the reaffirmed $68 million to $75 million adjusted EBITDA target after Q1 adjusted EBITDA of $9.2 million 8-K.
Whether Canadian cannabis share recovers as Quebec cultivation output ramps in the second half and supply issues in flower and pre-rolls ease 6.
Whether BrewDog and Lyphe start to contribute enough operating benefit to offset integration, restructuring and transaction costs that were still elevated in Q1 1920.
Produced by Clarifo Research with the Clarifo financial research engine from the company's reported filings. AI was used in parts of the analysis and drafting. Figures come from the reported financial statements, and figures in the text are checked automatically against the cited filing passages. This is not investment advice.